Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells ; volume:17 ; number:1 ; day:4 ; month:10 ; year:2017 ; pages:1-9 ; date:12.2017
Cancer cell international ; 17, Heft 1 (4.10.2017), 1-9, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Notarangelo, Tiziana
- Beteiligte Personen und Organisationen
-
Sisinni, Lorenza
Condelli, Valentina
Landriscina, Matteo
SpringerLink (Online service)
- DOI
-
10.1186/s12935-017-0457-z
- URN
-
urn:nbn:de:1111-20171129295
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Notarangelo, Tiziana
- Sisinni, Lorenza
- Condelli, Valentina
- Landriscina, Matteo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer